Physician profile
Abraham Cheriyan
NPI 1619034964
$3,707.15
in general payments reported to CMS, 2019-2025
28 companies · $24.59 in 2025
The $24.59 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $576 · 2020: $960 · 2021: $1,046 · 2022: $873 · 2023: $184 · 2024: $44.59 · 2025: $24.59.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $253.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $253.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $882.39 | 2019-2025 | Tezspire, Breztri, Fasenra |
| Glaxosmithkline, LLC. | $735.99 | 2019-2023 | Trelegy Ellipta, Nucala |
| Boehringer Ingelheim Pharmaceuticals, INC. | $636.26 | 2019-2023 | Ofev |
| Mylan Specialty L.P. | $163.79 | 2020-2024 | Yupelri |
| Philips North America LLC | $155.91 | 2020-2022 | |
| Intuitive Surgical, INC. | $139.85 | 2019 | |
| Pfizer INC. | $131.41 | 2019-2021 | |
| Harmony Biosciences LLC | $100.65 | 2020-2022 | |
| Janssen Pharmaceuticals, INC | $85.70 | 2021-2022 | |
| Genentech USA, INC. | $71.77 | 2019-2023 | Xolair |
| Actelion Pharmaceuticals US, INC. | $71.43 | 2019-2021 | |
| Eisai INC. | $56.69 | 2020 | |
| Electromed, INC. | $55.62 | 2021-2022 | |
| Optinose US, INC. | $54.03 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $54.00 | 2020-2021 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $50.56 | 2021-2022 | |
| Teva Pharmaceuticals USA, INC. | $39.78 | 2021 | |
| Genzyme Corporation | $33.91 | 2020-2022 | |
| Gilead Sciences, INC. | $30.81 | 2021 | |
| Insmed, INC. | $22.97 | 2020 | |
| Inogen, INC. | $19.88 | 2020 | |
| Kaleo, INC. | $19.12 | 2021 | |
| Advanced Respiratory, INC | $18.07 | 2021 | |
| Incyte Corporation | $17.49 | 2022 | |
| Csl Behring | $16.82 | 2019 | |
| Inspire Medical Systems, INC. | $14.96 | 2023 | Inspire |
| Baxter Healthcare | $14.40 | 2023 | Hillrom - Life 2000 Ventilation System |
| Jazz Pharmaceuticals INC. | $12.89 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Abraham Cheriyan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.